Evidence map›Paper›PMID 40017897›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort.

Giulio Disanto, Sabine Schaedelin, Johanna Oechtering, Johannes Lorscheider, Riccardo Galbusera, Sebastian Finkener, Lutz Achtnichts, Patrice Lalive, Stefanie Müller, Caroline Pot and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Giulio DisantoMultiple Sclerosis Center, Department of Neurology, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.ORCID https://orcid.org/0000-0002-8512-6096
Sabine SchaedelinNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Johanna OechteringNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Johannes LorscheiderNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Riccardo GalbuseraNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-3092-8737
Sebastian FinkenerDepartment of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.
Lutz AchtnichtsDepartment of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland.
Patrice LaliveDepartment of Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology, University Hospital of Geneva and Faculty of Medicine, Geneva, Switzerland.
Stefanie MüllerDepartment of Neurology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
Caroline PotDepartment of Clinical Neurosciences, Service of Neurology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-1146-3129
Robert HoepnerDepartment of Neurology, Bern University Hospital, University of Bern, Bern, Switzerland.
Anke SalmenDepartment of Neurology, Bern University Hospital, University of Bern, Bern, Switzerland.
Chiara ZeccaMultiple Sclerosis Center, Department of Neurology, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.ORCID https://orcid.org/0000-0002-9990-3431
Lars G HemkensResearch Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland.
Marcus D'SouzaNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-5175-9541
Bettina Fischer-BarnicolNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Renaud Du PasquierDepartment of Clinical Neurosciences, Service of Neurology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Patrick RothDepartment of Neurology, University Hospital Zurich and University of Zurich, Zürich, Switzerland.
Özgür YaldizliNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Maximilian EinsiedlerNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-0786-2872
Tobias DerfussNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-8431-8769
Ludwig KapposNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0003-4175-5509
Claudio GobbiMultiple Sclerosis Center, Department of Neurology, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.ORCID https://orcid.org/0000-0002-7554-0664
Cristina GranzieraNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0002-4917-8761
Marjolaine UginetDepartment of Clinical Neurosciences, Division of Neurology, Unit of Neuroimmunology, University Hospital of Geneva and Faculty of Medicine, Geneva, Switzerland.
Aleksandra Maleska MaceskiNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Keltie McDonaldCytel, London, UK.ORCID https://orcid.org/0000-0002-0204-9049
David LeppertNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Pascal BenkertNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-6525-8174
Jens KuhleNeurology, Multiple Sclerosis Center, Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Swiss MS Cohort Study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Persistence to B cell depleting therapies (BCDT) like ocrelizumab and rituximab may be higher compared with other disease-modifying therapies (DMT) in multiple sclerosis (MS). Clinical trials directly comparing these treatments are lacking. Objective: To compare the risk of treatment discontinuation, relapse, and confirmed disability worsening in patients starting BCDT vs other DMT within real-world settings. Methods: In a longitudinal cohort study, patients with relapsing MS starting BCDT (ocrelizumab/rituximab, Results: Patients starting BCDT were less likely to discontinue treatment than all other DMT combined (HR = 0.26, 95% CI = 0.18-0.36, Conclusion: We provide real-world evidence for patients being more persistent to BCDT than to other treatments, and better clinical outcomes may partly explain this.

Indexed as

clinical outcomesdisease-modifying treatmentMultiple sclerosispersistence

Identifiers

PMID40017897
PMCPMC11866361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.